Vectura Group PLC (LON:VEC) had its price objective decreased by equities researchers at J P Morgan Chase & Co from GBX 240 ($3.04) to GBX 210 ($2.66) in a report released on Friday, May 12th. The firm currently has an “overweight” rating on the stock. J P Morgan Chase & Co’s price target points to a potential upside of 86.17% from the stock’s previous close.
VEC has been the topic of a number of other research reports. Numis Securities Ltd reaffirmed a “buy” rating and set a GBX 225 ($2.85) target price on shares of Vectura Group PLC in a report on Friday, March 17th. Peel Hunt reiterated a “buy” rating and set a GBX 200 ($2.53) price target on shares of Vectura Group PLC in a research report on Friday, February 24th. Stifel Nicolaus reiterated a “buy” rating and set a GBX 225 ($2.85) price target on shares of Vectura Group PLC in a research report on Tuesday, January 24th. Finally, Citigroup Inc. reiterated a “buy” rating and set a GBX 225 ($2.85) price target on shares of Vectura Group PLC in a research report on Thursday, March 30th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of GBX 210.13 ($2.66).
Shares of Vectura Group PLC (LON VEC) opened at 112.80 on Friday. The company has a 50 day moving average price of GBX 124.51 and a 200 day moving average price of GBX 138.92. The company’s market capitalization is GBX 764.39 million. Vectura Group PLC has a 12-month low of GBX 110.17 and a 12-month high of GBX 166.97.
Vectura Group PLC Company Profile
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.
What are top analysts saying about Vectura Group PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Vectura Group PLC and related companies.